A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs

European Journal of Health Economics

Volumn 17, Issue 4, 2016, Pages 391-402

  Krol, Marieke ^a   Papenburg, Jocé ^b   Tan, Siok Swan ^a   Brouwer, Werner ^a   Hakkaart, Leona ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Economic evaluation; Indirect costs; Productivity costs; Systematic review

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AMINOLEVULINIC ACID METHYL ESTER; ANIDULAFUNGIN; BEVACIZUMAB; BORTEZOMIB; CASPOFUNGIN; CETUXIMAB; DOCETAXEL; DOXORUBICIN; DROTRECOGIN; GEMCITABINE; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IRINOTECAN; NATALIZUMAB; NAVELBINE; OMALIZUMAB; OXALIPLATIN; PACLITAXEL; PALIFERMIN; PANITUMUMAB; PEGAPTANIB; PEMETREXED; RANIBIZUMAB; RITUXIMAB; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VORICONAZOLE; PRESCRIPTION DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH STATUS; HUMAN; INCOME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRODUCTIVITY; SYSTEMATIC REVIEW; WORK CAPACITY; COST BENEFIT ANALYSIS; ECONOMICS; HOSPITAL COST; ORGANIZATION AND MANAGEMENT;

COST-BENEFIT ANALYSIS; EFFICIENCY, ORGANIZATIONAL; HOSPITAL COSTS; PRESCRIPTION DRUGS;

EID: 84927916119     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-015-0685-x     Document Type: Article

References (66)

1. ISPOR: pharmacoeconomic guidelines around the world. http://www.ispor.org/PEguidelines/index.asp. Accessed 18 Aug 2011
2. National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal (2008)
3. Johannesson M., Jönsson, B., Jönsson, L., Kobelt, G., Zethraeus, N.: Why should economic evaluations of medical innovations have a societal perspective? OHE briefing (2009)
4. Jonsson, B.: Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 10, 357–359 (2009)
5. Johannesson, M.A.: Note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy 33, 59–66 (1995)
6. Gold, M., Siegel, J., Russell, L., Weinstein, M.: Cost-effectiveness in health and medicine. Oxford University Press, Oxford (1996)
7. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J., Stoddart, G.L.: Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford (2005)
8. Claxton, K., Walker, S., Palmer, S., Sculpher, M.: Appropriate perspectives for health care decisions. CHE Reasearch paper 54 (2010)
9. The government’s response to the Health Select Committee’s eighth report of session 2012–13 on the National Institute for Health and Clinical Excellence (2013)
10. Brouwer, W.B., Koopmanschap, M.A., Rutten, F.F.: Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 6, 511–514 (1997)
11. Krol, M., Papenburg, J., Koopmanschap, M., Brouwer, W.: Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics 29, 601–619 (2011)
12. Stone, P.W., Chapman, R.H., Sandberg, E.A., Liljas, B., Neumann, P.J.: Measuring costs in cost-utility analyses. Variations in the literature. Int. J. Technol. Assess. Health Care 16, 111–124 (2000)
13. Pritchard, C., Sculpher, M.: Productivity costs: principles and practice in economic evaluation. Office of Health Economics, London (2000)
14. Brouwer, W.B.F., Exel, J.A., Baltussen, R.M.P.M., Rutten, F.F.H.: A dollar is a dollar—or is it? Value Health 9, 341–347 (2006)
15. Rothermich, E.A., Pathak, D.S.: Productivity-cost controversies in cost-effectiveness analysis: review and research agenda. Clin. Ther. 21, 255–267 (1999)
16. Gerard, K.: Cost-utility in practice: a policy maker’s guide to the state of the art. Health Policy 21, 249–279 (1992)
17. Hoffmann, C., Graf von der Schulenburg, J.: The influence of economic evaluation studies on decision making. A European survey. EUROMET Group 52, 179–192 (2000)
18. Tang, K.: Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence. Pharmacoeconomics 33, 31–48 (2014)
19. Zhang, W., Bansback, N., Anis, A.H.: Measuring and valuing productivity loss due to poor health: a critical review. Soc. Sci. Med. 72, 185–192 (2011)
20. Krol, M., Brouwer, W.: How to estimate productivity costs in economic evaluations. Pharmacoeconomics 32, 335–344 (2014)
21. Krol, M., Brouwer, W., Rutten, F.: Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics, (2013)
22. Weisbrod, B.A.: The valuation of human capital. J. Polit. Econ. 69, 425–436 (1961)
23. Koopmanschap, M.A., Rutten, F.F., van Ineveld, B.M., van Roijen, L.: The friction cost method for measuring indirect costs of disease. J Health Econ 14, 171–189 (1995)
24. Koopmanschap, M.A., Rutten, F.F.: The impact of indirect costs on outcomes of health care programs. Health Econ. 3, 385–393 (1994)
25. Lindholm, L., Lofroth, E., Rosen, M.: Does productivity influence priority setting? A case study from the field of CVD prevention. Cost Eff Resour Alloc 6, 6 (2008)
26. Olsen, J., Richardson, J.: Production gains from health care: what should be included in cost-effectiveness analysis. Soc. Sci. Med. 49, 17–26 (1999)
27. Williams, A.: Cost-effectiveness analysis: is it ethical? J. Med. Ethics 18, 7–11 (1992)
28. Australian Government Department of Health and Ageing: Pharmaceutical Benefits Advisory Committee: Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. December (2008)
29. Grocott, R., Metcalfe, S., Schoeler, R., Priest, V., Hall, C., Brougham, M., Poynton, M.: Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. PHARMAC Pharmaceutical Management Agency (2007)
30. Hoffman, J.M., Li, E., Doloresco, F., Matusiak, L., Hunkler, R.J., Shah, N.D., Vermeulen, L.C., Schumock, G.T.: Projecting future drug expenditures in US nonfederal hospitals and clinics–2013. Am. J. Health Syst. Pharm. 70, 525–539 (2013)
31. Nederlandse zorgautoriteit: http://www.nza.nl/137706/145406/CI-1135.pdf (2009). Accessed 22 June 2013
32. Eurostat: annual average rate of change in harmonized indices of consumer prices (HICPs). http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=en&pcode=tsieb060. Accessed 03 July 2011
33. van den Hout, W.B., Goekoop-Ruiterman, Y.P., Allaart, C.F., de Vries-Bouwstra, J.K., Hazes, J.M., Kerstens, P.J., van Zeben, D., Hulsmans, H.M., de Jonge-Bok, J.M., de Sonnaville, P.B., Dijkmans, B.A., Breedveld, F.C.: Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 61, 291–299 (2009)
34. Norum, J., Holtmon, M.: Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective? Acta Oncol. 44, 735–741 (2005)
35. Walsh, C.A., Minnock, P., Slattery, C., Kennedy, N., Pang, F., Veale, D.J., Bresnihan, B., FitzGerald, O.: Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 46, 1148–1152 (2007)
36. Maniadakis, N., Fragoulakis, V., Pectasides, D., Fountzilas, G.: XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr. Med. Res. Opin. 25, 797–805 (2009)
37. Kobelt, G., Sobocki, P., Sieper, J., Braun, J.: Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int. J. Technol. Assess. Health Care 23, 368–375 (2007)
38. Kobelt, G., Andlin-Sobocki, P., Brophy, S., Jönsson, L., Calin, A., Braun, J.: The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 43, 1158–1166 (2004)
39. Gani, R., Giovannoni, G., Bates, D., Kemball, B., Hughes, S., Kerrigan, J.: Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 26, 617–627 (2008)
40. Bristow, R.E., Santillan, A., Salani, R., Diaz-Montes, T.P., Giuntoli, R.L., Meisner, B.C., Armstrong, D.K., Frick, K.D.: Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Gynecol. Oncol. 106, 476–481 (2007)
41. Davies, A., Cifaldi, M.A., Segurado, O.G., Weisman, M.H.: Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J. Rheumatol. 36, 16–26 (2009)
42. Spalding, J.R., Hay, J.: Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 24, 1221–1232 (2006)
43. Kobelt, G., Andlin-Sobocki, P., Maksymowych, W.P.: The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J. Rheumatol. 33, 732–740 (2006)
44. Wong, J.B., Singh, G., Kavanaugh, A.: Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400–408 (2002)
45. Manns, B.J., Lee, H., Doig, C.J., Johnson, D., Donaldson, C.: An economic evaluation of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347, 993–1000 (2002)
46. Lindgren, P., Geborek, P., Kobelt, G.: Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from southern Sweden. Int. J. Technol. Assess. Health Care 25, 181–189 (2009)
47. Dewilde, S., Turk, F., Tambour, M., Sandström, T.: The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr. Med. Res. Opin. 22, 1765–1776 (2006)
48. Kobelt, G., Sobocki, P., Mulero, J., Gratacos, J., Collantes-Estevez, E., Braun, J.: The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. Scand. J. Rheumatol. 37, 62–71 (2008)
49. Kobelt, G., Eberhardt, K., Geborek, P.: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis. 63, 4–10 (2004)
50. Kobelt, G., Jönsson, L., Young, A., Eberhardt, K.: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 42, 326–335 (2003)
51. Kobelt, G., Berg, J., Lindgren, P., Jonsson, B., Stawiarz, L., Hillert, J.: Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult. Scler. 14, 679–690 (2008)
52. Norum, J., Olsen, J.A., Wist, E.A., Lønning, P.E.: Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol. 46, 153–164 (2007)
53. Boonen, A., van der Heijde, D., Severens, J.L., Boendermaker, A., Landewé, R., Braun, J., Brandt, J., Sieper, J., van der Linden, S.: Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann. Rheum. Dis. 65, 201–208 (2006)
54. Lidgren, M., Jönsson, B., Rehnberg, C., Willking, N., Bergh, J.: Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann. Oncol. 19, 487–495 (2008)
55. McCabe, C., Claxton, K., Culyer, A.J.: The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26, 733–744 (2008)
56. Raad voor de Volksgezondheid en Zorg: Zinnige en duurzame zorg. http://www.rvz.net/data/download/advies_Zinnige_zorg.pdf (2006). Accessed 22 June 2013
57. Meltzer, D.: Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16, 33–64 (1997)
58. Meerding, W.J., IJzelenberg, W., Koopmanschap, M.A., Severens, J.L., Burdorf, A.: Health problems lead to considerable productivity loss at work among workers with high physical load jobs. J. Clin. Epidemiol. 58, 517–523 (2005)
59. Zhang, W., Gignac, M.A., Beaton, D., Tang, K., Anis, A.H.: Canadian Arthritis Network Work Productivity Group: productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J. Rheumatol. 37, 1805–1814 (2010)
60. Brouwer, W.B., Koopmanschap, M.A.: The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics 23, 105–111 (2005)
61. Birnbaum, H.: Friction-cost method as an alternative to the human-capital approach in calculating indirect costs. Pharmacoeconomics 23, 103–104 (2005)
62. Brouwer, W.B., Koopmanschap, M.A., Rutten, F.F.: Productivity costs measurement through quality of life? A response to the recommendation of the Washington panel. Health Econ. 6, 253–259 (1997)
63. Johannesson, M., Karlsson, G.: The friction cost method: a comment. J. Health Econ 16, 249–255 (1997). (discussion 257–259)
64. Nyman, J.: Productivity costs revisited: toward a new US policy. Health Econ. 21, 1387–1401 (2012)
65. Tilling, C., Krol, M., Tsuchiya, A., Brazier, J., Brouwer, W.: In or out? Income losses in health state valuations: a review. Value Health 13, 298–305 (2010)
66. Knies, S., Severens, J.L., Ament, A.J., Evers, S.M.: The transferability of valuing lost productivity across jurisdictions. Differences between national pharmacoeconomic guidelines. Value Health 13, 519–527 (2010)